Clinical Trials

Kadmon is dedicated to developing innovative, safe and effective therapies for patients

Kadmon is committed to providing clear, current and accessible information about our novel product candidates to patients and healthcare providers. To learn more about ongoing clinical trials or to find out if a study is enrolling patients in your area, please visit www.clinicaltrials.gov or send an email to clinical@kadmon.com.

Oncology: Non-Small Cell Lung Cancer (NSCLC)

Brief

Study to assess the activity of tesevatinib in subjects with NSCLC with activating EGFR mutations and brain metastases or leptomeningeal metastases.

Information
Phase: 2
Study Ref. #: KD019-206

Autoimmune Disease: Psoriasis

Brief

Study to evaluate the safety, tolerability, and efficacy of KD025 in adult subjects with moderate to severe chronic plaque psoriasis.

Information
Phase: 2
Study Ref. #: KD025-211

Fibrotic Diseases: Idiopathic Pulmonary Fibrosis

Brief

A randomized, phase 2, open-label, multicenter study to evaluate the safety, tolerability, and activity of KD025 in subjects with idiopathic pulmonary fibrosis (IPF)

Information
Phase: 2
Study Ref. #: KD025-207

Autoimmune Disease: cGVHD

Brief

Study to evaluate the safety, tolerability, and activity of KD025 in adult subjects with chronic graft-versus-host disease (cGVHD).

Information
Phase: 2
Study Ref. #: KD025-208

Monogenic Diseases: Autosomal Dominant Polycystic Kidney Disease

Brief

Safety, pharmacokinetic and dose-escalation study of tesevatinib (KD019) in subjects with Autosomal Dominant Polycystic Kidney Disease.

Information
Phase: 2a
Study Ref. #: KD019-101

Oncology: Glioblastoma

Brief

Study to assess the activity of tesevatinib in patients with recurrent glioblastoma.

Information
Phase: 2
Study Ref. #: KD019-208